protease. Amino-terminal sequence analysis of the isolated 25,000-D heparin-binding domain of N-CAM yielded the sequence: Leu-Gln-Val-Asp-Ile-Val-Pro-SerGln-Gly. This sequence is identical to the previously reported amino-terminal sequence for murine and bovine N-CAM. Thus, the 25,000-D polypeptide fragment is the amino-terminal region of the N-CAM molecule. We have also shown that the BIA3 mAb recognizes not only chicken N-CAM but also rat and mouse N-CAM, indicating that the heparin-binding domain of N-CAM is evolutionarily conserved among different N-CAM forms. Additional peptide-mapping studies indicate that the second cell-binding site of N-CAM is located in a polypeptide region at least 65,000 D from the amino-terminal region. We conclude that the adhesion domains on N-CAM identified by these antibodies are physically distinct, and that the previously identified cell-binding domain on Frl is the heparin-binding domain.
T
HE specific recognition between neuronal cell types is of critical importance during neural development. Cell-cell interactions have been the focus of many recent studies, and several distinct cell surface molecules have been implicated in neuronal cell-cell adhesion. These molecules include the neural cell adhesion molecule N-CAM (10, 13, 17, 23, 29) , neuron-glial cell adhesion molecule (Ng-CAM) (11) , L1 (21) , and the nerve growth factor-inducible large external (NILE) glycoprotein (28) . N-CAM is the best characterized neural cell adhesion molecule to date, and has been implicated in neuron-neuron (24, 25, 29) , neuron-muscle (12) , and neuron-glial (18, 27 ) adhesion. Previous studies have examined the relationship between the chemical properties of N-CAM and its function, and have shown that a site required for homophilic binding of N-CAM (14) is localized to the amino-terminal region of the molecule (9) .
Studies in our laboratory have characterized a neural cell adhesion molecule that has now been identified as N-CAM (3-7). Using monoclonal antibodies, we have characterized the role of N-CAM in neuronal cell interactions. The BtA3 mAb, which inhibits cell-cell adhesion, recognizes a 25,000-D polypeptide fragment from N-CAM that binds specifically to heparin or heparan sulfate (5) . We have also demonstrated that heparin or heparan sulfate can inhibit N-CAM-mediated cell interactions (5, 6) . A second mAb (C1H3) also inhibits N-CAM-mediated cell-cell or cell-substratum adhesion but does not bind to the 25,000-D fragment. In the present study we were interested in determining the topographical localization of the heparin-binding domain and how it may be related to the location of the cell-binding domain. Our data indicate that the heparin-binding domain is localized to the 25,000-D amino-terminal region of the N-CAM molecule.
Materials and Methods

Preparation of mAb's
The preparation and characterization of the B~A3 mAb (5), as well as other mAb's (3), has been described previously. The BtA3 mAb was produced by immunizing BALB/c mice with immunopurified N-CAM. The B~A3 and C~H3 antibodies react with different epitopes, since they do not inhibit the binding of each other to N-CAM. Neither antibody binds to carbohydrate, each reacts with protein isolated from cells labeled with [35S]methionine for 30 min, as described in reference 3, or with N-CAM synthesized by retina cells in the presence of tunicamycin.
Immunopurification of N-CAM
N-CAM was immunopurified from embryonic day 14 chicken brain tissue as previously described (7) . Briefly, for each purification 100-200 brains were removed and homogenized in calcium-magnesium-free Hanks' solution, and a membrane fraction was isolated. The membranes were then solubilized in PBS containing 1 mM EDTA and 0.5% NP-40 (pH 8,3). CIH3 mAb, which reacts with N-CAM (5), was coupled to cyanogen bromide-activated Sepharose 4B (•5-7 mg/ml). The solubilized extract of brain membranes was then incubated with the C~H3-Sepharose, and bound protein was eluted with PBS/1 mM EDTA/0.5 % NP-40 containing 0.05 M diethylamine (pH 11.5).
Preparation of Heparin-binding Domain from N-CAM
The heparin-binding domain was prepared from N-CAM by proteolytic digestion of immunopurified N-CAM with subtilisin protease (5). For amino-terminal sequencing of the heparin-binding domain, 2 mg of N-CAM was incubated with 40 Ixg of subtilisin protr, ase (Sigma Chemical Co., St. Louis, MO) at 37°C for 1 h. Proteolysis was then stopped by the addition of phenylmethylsulfonyl fluoride (PMSF) and aprotinin (Sigma Chemical Co.). The digested N-CAM (in 0.Ix PBS) was then incubated with 1.5 rod of heparin-agarose (Sigma Chemical Co.) for 1.5 h at room temperature, and packed into a column. After washing with 0.1× PBS, the heparinbinding fragment was eluted with 0.5 M NaC1.
Immunoblotting Analysis of N-CAM
To determine if the BjA3 mAb recognized a similar epitope in rat N-CAM, rat or chicken N-CAMs were digested with subtilisin protease (1:50 enzyme/substrate ratio) and electrophoresed on 10 % polyacrylamide gels. The proteolytic fragments were then transfenvA to nitrocellulose and reacted with BIA3 mAb as previously described (3, 5). mAb binding was visualized using the avidin-biotin conjugate method (Vector Laboratories, Inc., Burlingame, CA).
Amino-terminal Sequencing of Isolated
Heparin-binding Domain
After isolation of the heparin-binding domain, the 25,000-D fragment was electrophoresed on a 10% polyacrylamide mini-gel and stained with Coomassie Blue for 10 min. The gel was then rapidly destained (15) , and the bands corresponding to the 25,000-D fragment were cut from the gel. The gel fragments were then processed for electroelution as described by Hunkapiller et al. (15) . Alternatively, we transferred the 25,000-D fragment to polybrene-coated glass fiber filters (30) . We initially attempted to obtain sequence analysis by electroblotting the 25,000-D fragment onto activated glass filter paper (1), but the fragment did not transfer out of the gel onto the glass filter paper. We thus initially used the electroelution method to obtain sequence information and then confirmed the amino-terminal sequence by transfer of the 25,000-D fragment to polybrene-coated glass fiber filters. After electroelution of the 25,000-D fragment or identification of the fragment on the glass fiber paper, amino-terminal sequence analysis was performed on a vapor phase sequencer (model 470A; Applied Biosystems, Inc., Foster City, CA) with identification of the phenylthiohydantoin amino acids on an on-line phenylthiohydantoin analyzer (model 120A; Applied Biosystems, Inc.).
Results
Cunningham et al. (9) demonstrated that a 65,000-D polypeptide fragment could be derived from N-CAM by autodigestion of N-CAM, and that this fragment (named Frl) could inhibit N-CAM-mediated cell binding. This fragment could also be isolated by digestion of N-CAM with Staphylococcus aureus V8 protease (14) , and it was shown that the amino-terminal amino acid sequence of Frl was identical to the intact protein (9) . It was therefore concluded that the cellbinding domain of N-CAM was localized to the amino terminus of the molecule.
In the present study we were interested in determining the topographical localization of the heparin-binding domain of N-CAM. Our laboratory has shown that heparin or the physiologically relevant ligand heparan sulfate are involved in N-CAM-mediated cell-cell interactions (5, 6) . It has also been demonstrated that N-CAM undergoes a conformational change after the binding of heparan sulfate (7) . Therefore, it is of interest to examine how the alignment of the heparinbinding domain on the linear sequence of the N-CAM molecule is related to the cell-binding region.
Our initial studies regarding the binding characteristics of the BIA3 mAb, which recognizes the heparin-binding domain of N-CAM, showed that the BIA3 mAb reacts with a 65,000-D polypeptide fragment that is converted to the 25,000-D fragment with more extensive protease treatment (5). We were therefore interested in determining if the 65,000-D Frl fragment was identical to the fragment recognized by the B~A3 mAb. In preliminary experiments, we attempted to obtain the Frl fragment by autodigestion of N-CAM at 37°C, as described by Edelman and co-workers (9) . We only obtained limited amounts of the Frl fragment, which suggests that our N-CAM preparations do not contain significant quantities of protease activity; however, the Frl fragment that we generated reacted with the B~A3 mAb (data not shown). To obtain more direct evidence that the BIA3 mAb recognized the cell-binding domain of N-CAM, we treated N-CAM with S. aureus V8 protease and then performed an immunoblotting analysis ( Fig. 1 ). As shown in Fig. 1 , lane a, when N-CAM is reacted with subtilisin protease and then incubated with BIA3 mAb, both 65,000-and 25,000-D polypeptide fragments are detected. After longer incubations with subtilisin protease, the 25,000-D fragment is the only fragment to which the BIA3 mAb can bind (5). Likewise, when N-CAM is digested with V8 protease, the BtA3 mAb reacts with a 65,000-D fragment, which is presumably the Frl fragment of N-CAM. These data therefore indicate that the heparin-binding domain of N-CAM is probably localized to the 65,000-D amino-terminal region of the N-CAM protein, and raises the question of whether the cell-binding domain is identical to the heparin-binding domain. 
The amino acid sequence of the 25,000-D heparin-binding fragment was determined as described under Materials and Methods. The sequence is shown through the first 10 residues, although cycles 11-15 yielded a low level sequence that also matched the amino-terminal sequence of N-CAM. Three independent analyses were performed.
Our data in Fig. 1 also show that the C1H3 mAb, which inhibits cell-substratum and cell-cell adhesion (4-6), reacts with a polypeptide fragment distinct from Frl. Since the cin3 mAb does not bind to Frl, these data suggest that the C1H3 mAb binding site must be at least 65,000-D from the amino terminus of N-CAM. These data also imply that at least two functional domains may exist on N-CAM and that the CIH3 mAb might bind to a region of the N-CAM molecule that participates in homophilic binding.
To determine whether the heparin-and cell-binding domains are both localized to the amino-terminal region, we performed amino-terminal amino acid sequence analysis of the isolated heparin-binding domain. As shown in Table I , the amino acid sequence obtained for the 25,000-D fragment is Leu-Gln-Val-Asp-Ile-Val-Pro-Ser-Gln-Gly, which is identical to the previously reported amino-terminal sequence for N-CAM (22). Thus, these data indicate that the heparinbinding domain of N-CAM is localized within the 25,000-D of the amino-terminal region of the molecule.
Rougon and Marshak (22) produced antibodies that recognized a synthetic peptide sequence derived from the aminoterminal sequence of murine and bovine N-CAM. These antibodies cross-reacted with N-CAMs from a variety of species, which indicated that the amino-terminal domain iS highly conserved. Since the BjA3 mAb recognizes ~e heparin-binding domain from N-CAM and also blocks heparin binding to N-CAM, as well as the adhesive functionof the molecule, and the heparin-binding domain is localized to the amino-terminal region of N-CAM, we asked whether this domain is also conserved among different N-CAM species. To test this possibility, rat N-CAM was digested with subtilisin protease, transferred to nitrocellulose, and immunoblotted with BIA3 mAb. As shown in Fig. 2 , the B1A3 mAb reacts with 25,000-D polypeptide fragments obtained from both chicken and rat N-CAM. However, reaction of the mAb with rat N-CAM is weaker than with chicken N-CAM, which suggests that the epitopes may not be identical in both a and b) or an anti-rat N-CAM antiserum (lane c) as described in Fig. 1. species. In Fig. 2 it can also be seen that when chicken N-CAM is digested with subtilisin protease and blotted with an anti-rat N-CAM antiserum, only the 25,000-D fragment is stained (Fig. 2, lane c) . These data suggest that the most highly conserved region of chicken N-CAM, as detected by the anti-rat N-CAM antiserum, is the 25,000-D heparinbinding fragment. Alternatively, this fragment may be the most protease-resistant region of the N-CAM molecules when treated with subtilisin protease.
To confirm that the heparin-binding domain is a conserved structural and functional domain among various N-CAM forms, we used the B1A3 mAb to immunopurify N-CAM from metabolically labeled BC3H1 cells. The BC3H1 cell line is a mouse muscle-like cell line, and produces N-CAM (8) . Fig. 3 shows the results of an experiment involving the metabolic labeling of cultures of BC3H1 cells that were grown in 20% FCS and thus were undifferentiated (20) . Although the B1A3 mAb did not immunopurify significant quantities of labeled N-CAM from a BC3H1 cell extract, labeled N-CAM was isolated from the conditioned medium of the BC3H1 cells (Fig. 3) . These data indicate that the heparin-binding domain is conserved in mouse N-CAM, and also suggest that muscle cells (at least the BC3H1 cell line) may secrete larger amounts of N-CAM into the extracellular matrix than do neural cells. We have al~o analyzed N-CAM, immunopurified from adult mouse b~in or fiIC3H1 cells using BIA3 mAb, by immunoblotting~ using the anti-rat N-CAM antiserum. These experiments! showed that small amounts of N-CAM could be isolated from these cells using the BIA3 mAb (data not shown). The reason why only small amounts of N-CAM are isolated may be the low crossreactivity between mouse N-CAM and the BIA3 mAb. In light of these data demonstrating that the heparinbinding domain of N-CAM is localized in the aminoterminal region of the N-CAM molecule, we have constructed a linear model of the N-CAM molecule (Fig. 4) . Because our CIH3 mAb, which inhibits N-CAM-mediated cell-cell interactions, recognizes an epitope distinct from the B~A3 epitope (Fig. 1, lane c and reference 5) , we have assigned the ~ell-or homophilic-binding domain to a more internal region of the N-CAM molecule (Fig. 4 a) . However, it is possible that the cell-binding domain described by Edelman's laboratory (9) is also contained in the amino-terminal region of the N-CAM molecule (Fig. 4 b) and additional studies should provide information regarding the precise location of this functional domain.
Discussion
Our aim in the present study was to examine the relationship between the structure and function of the heparin-binding domain of N-CAM. Previous studies in our laboratory demonstrated that N-CAM contains a heparin-binding domain (5) , and this domain appears to be an integral component of the N-CAM-mediated cell adhesion mechanism. When immunopurified N-CAM is covalently coupled to glass surfaces, retinal cell attachment is inhibited by the cin3 mAb and by heparin (5, 7) . Likewise, the isolated heparin-binding domain promotes cell attachment (5) and the B~Aa mAb inhibits cell-cell adhesion (6) . These data therefore imply that the binding of heparan sulfate to N-CAM is required for N-CAM-mediated cell interactions. Since previous studies had assigned a topographic location for the cell-or homophilic-binding domain (9), we were interested in determining the topographic location of the heparinbinding domain. This was of particular interest since the binding of heparan sulfate to N-CAM induces a conformational change in the N-CAM protein (7) . A similar conformational change has been described for fibronectin, and this leads to an increased affinity of fibronectin for other extracellular matrix components and for the cell surface (16) .
Our initial experiments suggested that the heparin-binding domain of N-CAM was identical to Frl, which was previously reported to be the cell-binding domain (9) . After amino-terminal amino acid sequencing of the isolated heparin-binding domain, it could be concluded that the heparin-binding domain was also localized in the aminoterminal region of the N-CAM molecule. These results raise an important question: is the previously identified cellbinding domain in fact the heparin-binding domain, or are both localized to the amino-terminal region of the protein? As shown in Fig. 4 a, we constructed a linear model for the structure of the N-CAM molecule that is based on the conclusion that the cell-binding region described by Cunningham et al. (9) is the heparin-binding domain. In this model we aligned the heparin-binding domain in the amino-terminal region, and the cell-binding domain in a more internal position (>65,000-D from the amino terminus). The rationale for this model is that the C1H3 mAh inhibits N-CAMmediated cell-cell adhesion (6) and binds to a polypeptide fragment that is distinct from Frl (Fig. 1 , lane c and reference 5). These data would therefore suggest that the cellbinding and heparin-binding domains are located on different polypeptide fragments. However, at this time, the cell-binding region cannot be defined unequivocally because although the CIH3 mAb epitope is not a component of Frl, it is unclear what region of N-CAM will contain this epitope. However, it is clear that the C1H3 epitope must be at least 40,000-D from the heparin-binding fragment. Thus, it is possible that the C1H3 epitope is located at the cleavage site for Frl, if alternative cleavage of N-CAM occurs during proteolysis. In this case, any cleavage generating Frl would destroy the CtH3 epitope, and alternative cleavage sites would give rise to the fragments that the CIH3 mAb does recognize (5). Therefore, it is possible that the C1H3 mAb epitope is along the region of the N-CAM molecule extending from the cleavage site of the Frl fragment to the carbohydrate-containing region, although this remains to be determined.
It should be noted that the proposal that the cell-binding domain (which we are assuming is localized in a region that the CIH3 mAb binds) is located more internally than Frl depends upon several assumptions. The first is that the C1H3 mAb binds to a region of the N-CAM molecule that is involved in homophilic binding. The second assumption is that the C1H3 mAb does not inhibit cell-cell adhesion by a nonspecific mechanism (i.e., steric hindrance). The latter seems unlikely since the C1H3 epitope is separated from the B1A3 epitope by a minimum of 40,000 D on the linear map of N-CAM. In addition, while B~A3 blocks the binding of heparin sulfate to N-CAM, C~H3 does not show this effect (7), hence steric blockage of the heparin binding site by CtH3 seems unlikely. However, until further experiments are conducted, we have constructed two linear models to describe the relationship between N-CAM structure and function (Fig. 4 a and b) . The second model, depicted in Fig. 4 b, is based on the hypothesis that both the cell-and heparinbinding domains are components of Frl. Since the cellbinding domain was identified as a 65,000-D polypeptide fragment (9) , and the heparin-binding domain as a 25,000-D fragment, it is possible that the cell-binding domain is localized at least 25,000 D from the amino terminus (Fig. 4 b) . If this is the case, then it could be proposed that after heparan sulfate (contained on a heparan sulfate proteoglycan) binding to N-CAM, the conformational change in N-CAM could modulate the binding of cells to the cell-binding domain, which is in close proximity to the heparin-binding domain. This model could therefore account for the experimental results of Cunningham et al. (9) and of this study. However, because the C1H3 mAb is not a component of Frl, in this model the CIH3 mAb would be expected to inhibit cell adhesion nonspecifically, since the cell-binding domain is not associated with the CIH3 epitope. At this time we favor the proposal (Fig. 4 a) that the cell-and heparin-binding domains reside on distinct polypeptide fragments and that the previously described cell-binding domain is the heparinbinding domain. Additional support for this hypothesis could be obtained by the isolation of a polypeptide fragment, distinct from the heparin-binding domain, that can promote (or inhibit, depending on the assay) neural cell attachment. It is also noteworthy that other mAb's that recognize N-CAM and inhibit cell-cell adhesion have now been shown to react with the 25,000-D heparin-binding domain (Frelinger, L., and U. Rutishauser, personal communication). This discussion assumes that only two sites on N-CAM are responsible for its adhesion function. Clearly other sites, possibly overlapping, could be required for this function and are not identified by these antibodies.
Because the studies of Cunningham et al. (9) demonstrated that the cell-binding domain is localized to the aminoterminal region of N-CAM, we have also considered a third possibility to reconcile the results of their study and the present work. It is interesting to speculate that the cell-(homophilic) and heparin-binding domains are identical, and that the heparin-binding domain is responsible for homophilic binding. In this mechanism, the heparin-binding domain would be binding to a region of N-CAM that is similar in structure to the carbohydrate moiety of heparan sulfate proteoglycan. For example, previous studies have described the presence of HNK-1/L2 carbohydrate epitope on N-CAM, and this carbohydrate epitope is proposed to be involved in neuronal cell interactions (19) . The precise structure of the HNK-1/L2 epitope on N-CAM is unknown, and it is unclear whether this carbohydrate epitope is an O-or N-linked moiety. However, this carbohydrate structure appears to be a 3-sulfated glucuronyl carbohydrate chain (also found in glycolipids in the nervous system; reference 2), and it is interesting to speculate that it may be able to interact with the heparin-binding domain of N-CAM.
We have also demonstrated in this study that the heparinbinding domain is conserved among N-CAMs from a variety of other species. The 25,000-D fragment could be derived from rat N-CAM, and the B~A3 mAb could immunopurify small amounts of N-CAM from a mouse muscle cell line. An interesting result of the muscle experiment is that greater amounts of N-CAM appear to be secreted from BC3HI cells into the conditioned medium when compared with neural cells. Since these cells produce adherons that promote cell-substratum attachment (26) , it is possible that N-CAM is involved in cell attachment to these adherons; however, adherons from these cells also contain fibronectin and other known matrix molecules (26) . The demonstration that the BIA3 mAb reacts with N-CAM from other species therefore supports the data of Rougon and Marshak (22), which showed that the amino-terminal domain of N-CAM is a conserved structure. The fact that the heparin-binding domain is also exposed on the cell surface, which is a prerequisite for interaction with neighboring cells, is consistent with their results.
In conclusion, in these studies we have described the topographic location of the heparin-binding domain and a cellular-binding domain from N-CAM, and have shown that the heparin-binding domain is a conserved structure localized in the amino-terminal region of the N-CAM molecule.
